Advertisement

68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

  • Alexander HeinzelEmail author
  • Dima Boghos
  • Felix M. Mottaghy
  • Florian Gaertner
  • Markus Essler
  • Dirk von Mallek
  • Hojjat Ahmadzadehfar
Original Article

Abstract

Purpose

To evaluate the use of 68Ga-PSMA PET/CT for monitoring response to 177Lu-617 PSMA radioligand therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Methods

Patients from the University Hospital Bonn and the University Hospital Aachen were retrospectively reviewed for this study. We included 48 patients with mCRPC who were treated with 177Lu-PSMA-617 and whose records included 68Ga-PSMA PET/CT imaging before the first and after the third or fourth treatment cycle. A treatment response based on 68Ga-PSMA PET/CT was defined according to a modified version of the PERCIST criteria. A decline in PSA level of ≥50% was considered the reference standard. The sensitivity, specificity, positive and negative predictive values, and ROC curves were calculated, and patient survival times in relation to the PET results were also analysed.

Results

68Ga-PSMA PET/CT had a sensitivity of about 85% and a specificity of between 55% and 65%. The negative and positive predictive values ranged between 70% and 78%. The fitted ROC area was 0.70. The survival time was about 19.6 months in patients with a treatment response, while nonresponders had a survival time of about 15.9 months. However, this difference between the groups was not statistically significant.

Conclusion

Our results indicate that 68Ga-PSMA PET/CT could be a useful tool for the evaluation of response to 177Lu-PSMA-617 radioligand therapy within a theranostic framework.

Keywords

Prostate cancer 177Lu-PSMA-617 68Ga-PSMA PET/CT Response monitoring 

Notes

Acknowledgments

We thank Tanja Berger of The Institute of Medical Statistics of RWTH Aachen University for reviewing the data analysis.

Compliance with ethical standards

Conflicts of interest

None.

Ethical approval

This study was approved by the Institutional Review Board of the University Hospital Aachen. Given the type of study (a retrospective analysis), the need for written informed consent was waived. All procedures were performed in accordance with the ethical standards of the institutional and/or national research committees and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Supplementary material

259_2019_4258_MOESM1_ESM.docx (35 kb)
ESM 1 (DOCX 35 kb)

References

  1. 1.
    Wong MC, Goggins WB, Wang HH, Fung FD, Leung C, Wong SY, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016;70:862–74.  https://doi.org/10.1016/j.eururo.2016.05.043.CrossRefPubMedGoogle Scholar
  2. 2.
    Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914–20.  https://doi.org/10.2967/jnumed.114.147413.CrossRefPubMedGoogle Scholar
  3. 3.
    Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528–39.  https://doi.org/10.1002/jcb.10661.CrossRefPubMedGoogle Scholar
  4. 4.
    Kratochwil C, Afshar-Oromieh A, Kopka K, Haberkorn U, Giesel FL. Current status of prostate-specific membrane antigen targeting in nuclear medicine: clinical translation of chelator containing prostate-specific membrane antigen ligands into diagnostics and therapy for prostate cancer. Semin Nucl Med. 2016;46:405–18.  https://doi.org/10.1053/j.semnuclmed.2016.04.004.CrossRefPubMedGoogle Scholar
  5. 5.
    Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Sayeg M, Leshch Y, et al. PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the Bad Berka experience since 2013. J Nucl Med. 2016;57:97S–104S.  https://doi.org/10.2967/jnumed.115.170167.CrossRefPubMedGoogle Scholar
  6. 6.
    Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85–90.  https://doi.org/10.2967/jnumed.116.183194.CrossRefPubMedGoogle Scholar
  7. 7.
    Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, et al. Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. J Nucl Med. 2016;57:1334–8.  https://doi.org/10.2967/jnumed.116.173757.CrossRefPubMedGoogle Scholar
  8. 8.
    Lutje S, Heskamp S, Cornelissen AS, Poeppel TD, van den Broek SA, Rosenbaum-Krumme S, et al. PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status. Theranostics. 2015;5:1388–401.  https://doi.org/10.7150/thno.13348.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Haberkorn U, Kopka K, Giesel F, Kratochwil C. Future trends in prostate cancer theranostics with PSMA ligands. Clin Transl Imaging. 2016;4:487–9.CrossRefGoogle Scholar
  10. 10.
    Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. (68)Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014–24.  https://doi.org/10.1007/s00259-017-3670-z.CrossRefPubMedGoogle Scholar
  11. 11.
    Fendler WP, Kratochwil C, Ahmadzadehfar H, Rahbar K, Baum RP, Schmidt M, et al. 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer. Nuklearmedizin. 2016;55:123–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.  https://doi.org/10.1016/j.ejca.2008.10.026.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Wallace T, Torre T, Grob M, Yu J, Avital I, Brücher B, et al. Current approaches, challenges and future directions for monitoring treatment response in prostate cancer. J Cancer. 2014;5:3–24.  https://doi.org/10.7150/jca.7709.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–50S.  https://doi.org/10.2967/jnumed.108.057307.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402–18.  https://doi.org/10.1200/jco.2015.64.2702.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Castello A, Macapinlac HA, Lopci E, Santos EB. Prostate-specific antigen flare induced by (223)RaCl2 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:2256–63.  https://doi.org/10.1007/s00259-018-4051-y.CrossRefPubMedGoogle Scholar
  17. 17.
    Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009;10:233–9.  https://doi.org/10.1016/s1470-2045(08)70340-1.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Eder M, Schafer M, Bauder-Wust U, Hull WE, Wangler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688–97.  https://doi.org/10.1021/bc200279b.CrossRefPubMedGoogle Scholar
  19. 19.
    Rauscher I, Maurer T, Fendler WP, Sommer WH, Schwaiger M, Eiber M. (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: how we review and report. Cancer Imaging. 2016;16:14.  https://doi.org/10.1186/s40644-016-0072-6.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Uprimny C, Kroiss AS, Fritz J, Decristoforo C, Kendler D, von Guggenberg E, et al. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence. Eur J Nucl Med Mol Imaging. 2017;44:1647–55.  https://doi.org/10.1007/s00259-017-3743-z.CrossRefPubMedGoogle Scholar
  21. 21.
    O JH, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280:576–84.  https://doi.org/10.1148/radiol.2016142043.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825–33.  https://doi.org/10.1016/s1470-2045(18)30198-0.CrossRefPubMedGoogle Scholar
  23. 23.
    Rahbar K, Afshar-Oromieh A, Jadvar H, Ahmadzadehfar H. PSMA theranostics: current status and future directions. Mol Imaging. 2018;17:1536012118776068.  https://doi.org/10.1177/1536012118776068.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Evangelista L, Bertoldo F, Boccardo F, Conti G, Menchi I, Mungai F, et al. Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons. Eur J Nucl Med Mol Imaging. 2016;43:1546–62.  https://doi.org/10.1007/s00259-016-3350-4.CrossRefPubMedGoogle Scholar
  25. 25.
    Hovels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63:387–95.  https://doi.org/10.1016/j.crad.2007.05.022.CrossRefPubMedGoogle Scholar
  26. 26.
    Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209.  https://doi.org/10.1007/s00259-014-2949-6.CrossRefPubMedGoogle Scholar
  27. 27.
    Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012;39:1085–6.  https://doi.org/10.1007/s00259-012-2069-0.CrossRefPubMedGoogle Scholar
  28. 28.
    Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95.  https://doi.org/10.1007/s00259-012-2298-2.CrossRefPubMedGoogle Scholar
  29. 29.
    Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11–20.  https://doi.org/10.1007/s00259-013-2525-5.CrossRefPubMedGoogle Scholar
  30. 30.
    Caroli P, Sandler I, Matteucci F, De Giorgi U, Uccelli L, Celli M, et al. (68)Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. Eur J Nucl Med Mol Imaging. 2018;45:2035–44.  https://doi.org/10.1007/s00259-018-4067-3.CrossRefPubMedGoogle Scholar
  31. 31.
    Mottaghy FM, Heinzel A, Verburg FA. Molecular imaging using PSMA PET/CT versus multiparametric MRI for initial staging of prostate cancer: comparing apples with oranges? Eur J Nucl Med Mol Imaging. 2016;43:1397–9.  https://doi.org/10.1007/s00259-016-3389-2.CrossRefPubMedGoogle Scholar
  32. 32.
    Filss C, Heinzel A, Miiller B, Vogg ATJ, Langen KJ, Mottaghy FM. Relevant tumor sink effect in prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy. Nuklearmedizin. 2018;57:19–25.  https://doi.org/10.3413/Nukmed-0937-17-10.CrossRefPubMedGoogle Scholar
  33. 33.
    Li X, Rowe SP, Leal JP, Gorin MA, Allaf ME, Ross AE, et al. Semiquantitative parameters in PSMA-targeted PET imaging with (18)F-DCFPyL: variability in normal-organ uptake. J Nucl Med. 2017;58:942–6.  https://doi.org/10.2967/jnumed.116.179739.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Keidar Z, Gill R, Goshen E, Israel O, Davidson T, Morgulis M, et al. 68Ga-PSMA PET/CT in prostate cancer patients – patterns of disease, benign findings and pitfalls. Cancer Imaging. 2018;18:39.  https://doi.org/10.1186/s40644-018-0175-3.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A, et al. [(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42:210–4.  https://doi.org/10.1007/s00259-014-2915-3.CrossRefPubMedGoogle Scholar
  36. 36.
    Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomacker K, et al. Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17:575–84.  https://doi.org/10.1007/s11307-015-0866-0.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678–88.  https://doi.org/10.1007/s00259-016-3573-4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Nuclear MedicineUniversity Hospital RWTH AachenAachenGermany
  2. 2.Institute for Neuroscience and Medicine (INM-4)Research Centre JülichJülichGermany
  3. 3.Department of Radiology and Nuclear MedicineMaastricht University Medical CenterMaastrichtThe Netherlands
  4. 4.Department of Nuclear MedicineUniversity Hospital BonnBonnGermany

Personalised recommendations